Update to Rociletinib Data with the RECIST Confirmed Response Rate.

  title={Update to Rociletinib Data with the RECIST Confirmed Response Rate.},
  author={Lecia V Sequist and Jean – Charles Soria and David Ross Camidge},
  journal={The New England journal of medicine},
  volume={374 23},
To the Editor: In our Journal article that was published on April 30, 2015,1 we described the activity of rociletinib, an epidermal growth factor receptor (EGFR) inhibitor with specificity for the T790M mutation, in patients with EGFR mutation–positive lung cancer in the phase 1 TIGER-X trial. The key finding was a response rate of 59% (95% confidence interval [CI], 45 to 73) among 46 patients with biopsy-proven T790Mmediated resistance to previously administered EGFR inhibitors. In November… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 37 times over the past 90 days. VIEW TWEETS
25 Citations
2 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 25 extracted citations


Publications referenced by this paper.

Similar Papers

Loading similar papers…